Peer Review History
| Original SubmissionMarch 23, 2020 |
|---|
|
PONE-D-20-08293 Tuberculosis preventive therapy should be considered for all household contacts of pulmonary tuberculosis patients in India PLOS ONE Dear Dr Paradkar, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. In particular, Reviewer #2 raised a number of points that need to be addressed carefully and thoroughly in a revised manuscript. We would appreciate receiving your revised manuscript by Jun 27 2020 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols Please include the following items when submitting your revised manuscript:
Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. We look forward to receiving your revised manuscript. Kind regards, Olivier Neyrolles Academic Editor PLOS ONE Journal requirements When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. Please consider modifying your title to ensure that it is specific, descriptive, concise, and comprehensible to readers outside the field. 3. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. In your revised cover letter, please address the following prompts: a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. We will update your Data Availability statement on your behalf to reflect the information you provide. Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: No ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: No ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: It is a well-designed study that will add the evidence on LTBI treatment. It is also well written and analyzed Abstract: No comment Introduction: No comment Methods: No comment Results: No comment Discussion: No comment Reference: No comment Reviewer #2: This is a well-designed prospective study that has tried to use mixed-effect Poisson regression for inferential data analyzed. The study has also included a high number of HHC to support the WHO recommendation. It is also a timely and relevant study in one of the high TB burden countries, INDIA. General comments This study has come up with an interesting and relevant finding that warrants a detailed and a bit extended discussion. Because the author is claiming/recommending TPT for all HHC and thus supporting the WHO recommendation. As compared to the findings, however, the discussion section is a bit brief and shorter. It seems there are other important findings that needs discussion; for example, why age, diabetes mellitus, and alcohol consumption are not related to iTBD? Could the way age (of HHC and index cases) was categorized, smoking and alcohol consumption were classified, and DM patients were presented logical and acceptable? This necessitates to revise the analysis section. There need to be a discussion as to why these are a not a factor for iTBD in this study, as compared to previous studies that verified as these are strong factors that are related to TB diseases, such as studies mentioned in references 2, 14, and 16. This can have importance in terms of prioritizing TPT in some low income countries who could not afford TPT for all HCC. This is a critical issue in need to be investigated. This is because, the authors are arguing and trying to convince strongly that no HHC is to be prioritized, no need to test for TBI prior to TPT provision. This requires answering the following questions. 1.Is it really feasible to provide TPT for all HHC considering limited logistics and availability of the newer combinations of drugs for TPT? 2.Which HHC to be given a priority? Hence, the authors justification and arguments need to be a bit stronger and discussed in detail so that NTPs will be convinced to provide TPT for HHC without any prioritization and testing using TST or IGRA. Besides, the way authors are listed and narrated, and their affiliation may be revised to align with the PLOS I format. The study could benefit from language revision; a bit longer and vague sentences are noted. The references as inserted in the body of the manuscript and listed in the reference need revision throughout. The formatting in the reference is not consistent and some are (E.g, reference # 5) incomplete. It is also worth considering the use of recent references; there are references older than 10 years (reference # 17, 21, 35, 36, 37, 44, and 48). At end, the headings in lines 136, 147, 164,251 and 287 need to be revised and well narrated; at least, the author need to avoid the use of abbreviations/acronyms in the headings. Specific comments 1. A sentence in Lines 32 and 33 is very important sentence but lacks clarity. In the same sentence, it is narrated that the study determined which HHC group are beneficial from TPT in India and other high TB burden country. Is that the real and specific objective of the study, as it was carried out among the Indian population? 2. TBD in line 35 should be fully written as it appeared for the first time. 3. A sentence in lines 33-36 could be revised to be narrated clearly and succinctly. As currently written, it is long and difficult to understand. 4. Line 59 & 60, the India’s contribution to the global TB incidence could be described in the form of proportion, 28% (2.8 of 10 million) or near to one-third of… Similarly, line 91 need to be revised. 5. Who were the children in your study (as related to age category)? Can we define them with reference? 6. A sentence in lines 108-110 is not clear and needs revision. 7. What was applied, oral or written informed consent? How was the consent of a child requested and obtained? 8. What are the specific psycho-social and medical history in lines 116 & 123, and household characteristics in line 132? 9. What is/are the reference (s) for the definition in lines 121-123 and 165-174? 10. A sentence in lines 126-131 is too long and better be narrated again. For example, presumptive TB cases should be defined, and which microbiological, tissue-based, or radiologically investigations are indicated for which specific signs or/and symptoms detected during the follow up? 11. Consider revision for a sentence in lines 141-143, seems two sentences. 12. A sentence in lines 148-149 lacks clarity. 13. On what basis was the age category made or classified as described in table 1? 14. Having TBD, and HHC without baseline TBI test the only exclusion criteria? 15. What IQR stands for in Line212-213? 16. Line 241-242 is not a result. The author may consider moving to data analysis section of the method. 17. The widowed and divorced ( as a sub-category of marital status) are with lower number to be categorized for the univariate and multivariate analysis. Consider categorizing these again. 18. What were the criteria to include the HHC characteristic to multivariate analysis? A lot of variables are not considered to be part of the cultivatable analysis, Table 1. For instance, p-value of 0.65 was included while p-value of 0.67 not included in the multivariate analysis. What does the sentence in lines 198-199 mean? These better be aligned with the way real analysis was made. 19. Where in the study have you applied the Fisher’s exact test and Wilcoxon rank sum tests? Because these were stated in lines 181-182. 20. How was the level of alcohol consumption and smoking level determined? If possible, objectively quantifying the degree of alcohol consumption and smoking is a better option. It seems that a fewer month’s period of smoking and alcohol consumption were lumped up with the heavy alcohol consumption and a longer period smoking. If the level or degree of smoking or alcohol consumption is not objectively defined, the relation or impact these have on the TBD is not well determined 21. Why Table 1 and 3 are written separately? Why not the author considers HHC characteristics in one go? The other option is that tables 1-3 could be presented in two forms; first table/s could be committed to the description of the HHC and index cases, and the second table/s could present the result of the univariate and multivariate analysis. 22. Check the consistency in the content of sentences in lines 66& 67, and lines 345 &346. 23. The sentence in lines 371-373 is critical yet needs revision to make it so clear. The way “resource’ is used makes the sentence a bit confusing. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: Yes: Muluken Aseresa Reviewer #2: No While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
Tuberculosis preventive treatment should be considered for all household contacts of pulmonary tuberculosis patients in India PONE-D-20-08293R1 Dear Dr. Paradkar, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Olivier Neyrolles Section Editor PLOS ONE Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #2: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #2: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #2: (No Response) ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #2: Yes: Zewdu Gashu Dememew |
| Formally Accepted |
|
PONE-D-20-08293R1 Tuberculosis preventive treatment should be considered for all household contacts of pulmonary tuberculosis patients in India Dear Dr. Paradkar: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Olivier Neyrolles Section Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .